Eli Lilly To Buy Kelonia In Deal Valued Up To $7 Billion
Eli Lilly has agreed to acquire cancer drug maker Kelonia in a deal valued at up to $7 billion, expanding the pharmaceutical company’s oncology portfolio. The agreement calls for Lilly to buy Kelonia, a company focused on developing cancer medicines. The deal value could reach $7 billion based on the terms disclosed in reporting on…
